Literature DB >> 19695790

Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma.

Mariam P Korah1, Natia Esiashvili, Claire M Mazewski, Roger J Hudgins, Mourad Tighiouart, Anna J Janss, Frederick P Schwaibold, Ian R Crocker, Walter J Curran, Robert B Marcus.   

Abstract

PURPOSE: To investigate the incidence, risks, severity, and sequelae of posterior fossa syndrome (PFS) in children with medulloblastoma. METHODS AND MATERIALS: Between 1990 and 2007, 63 children with medulloblastoma at Emory University and Children's Healthcare of Atlanta were treated with craniectomy followed by radiation. Fifty-one patients were assigned to a standard-risk group, and 12 patients were assigned to a high-risk group. Five patients had <1.5-cm(2) residual tumor, 4 had >or=1.5-cm(2) residual tumor, and the remainder had no residual tumor. Eleven patients had disseminated disease. Patients received craniospinal irradiation at a typical dose of 23.4 Gy or 36 Gy for standard- or high-risk disease, respectively. The posterior fossa was given a total dose of 54 or 55.8 Gy. Nearly all patients received chemotherapy following cooperative group protocols.
RESULTS: Median follow-up was 7 years. PFS developed in 18 patients (29%). On univariate analysis, brainstem invasion, midline tumor location, younger age, and the absence of radiographic residual tumor were found to be predictors of PFS; the last two variables remained significant on multivariate analysis. From 1990 to 2000 and from 2001 to 2007, the proportions of patients with no radiographic residual tumor were 77% and 94%, respectively. During the same eras, the proportions of patients with PFS were 17% and 39%. Only 4 patients had complete recovery at last follow-up.
CONCLUSIONS: The incidence of PFS increased in the latter study period and is proportional to more aggressive surgery. Children with midline tumors exhibiting brainstem invasion are at increased risk. With the increased incidence of PFS and the permanent morbidity in many patients, the risks and benefits of complete tumor removal in all patients need to be reexamined.

Entities:  

Mesh:

Year:  2009        PMID: 19695790     DOI: 10.1016/j.ijrobp.2009.04.058

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

Review 1.  The clinical importance of medulloblastoma extent of resection: a systematic review.

Authors:  Eric M Thompson; Alexa Bramall; James E Herndon; Michael D Taylor; Vijay Ramaswamy
Journal:  J Neurooncol       Date:  2018-05-23       Impact factor: 4.130

2.  Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.

Authors:  Juan Yuan; Núria Llamas Luceño; Bjoern Sander; Monika M Golas
Journal:  Cell Oncol (Dordr)       Date:  2017-04-20       Impact factor: 6.730

Review 3.  Cause and outcome of cerebellar mutism: evidence from a systematic review.

Authors:  Rosa Reed-Berendt; Bob Phillips; Susan Picton; Paul Chumas; Daniel Warren; John H Livingston; Ellen Hughes; Matthew C H J Morrall
Journal:  Childs Nerv Syst       Date:  2014-01-23       Impact factor: 1.475

Review 4.  Guidelines for Treatment and Monitoring of Adult Survivors of Pediatric Brain Tumors.

Authors:  Anna J Janss; Claire Mazewski; Briana Patterson
Journal:  Curr Treat Options Oncol       Date:  2019-02-09

5.  Preoperative chemotherapy in medulloblastoma: a change in treatment paradigm?

Authors:  Dong-Anh Khuong-Quang; Jordan R Hansford
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

6.  Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells.

Authors:  Monika A Davare; Sangeet Lal; Jennifer L Peckham; Suresh I Prajapati; Sakir H Gultekin; Brian P Rubin; Charles Keller
Journal:  Biochem Biophys Res Commun       Date:  2014-06-10       Impact factor: 3.575

Review 7.  Cerebellar mutism.

Authors:  G Tamburrini; P Frassanito; D Chieffo; L Massimi; M Caldarelli; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2015-09-09       Impact factor: 1.475

8.  A decision analysis tool for the assessment of posterior fossa tumour surgery outcomes in children--the "Liverpool Neurosurgical Complication Causality Assessment Tool".

Authors:  Rasheed Zakaria; Jonathan Ellenbogen; Catherine Graham; Barry Pizer; Conor Mallucci; Ram Kumar
Journal:  Childs Nerv Syst       Date:  2013-03-14       Impact factor: 1.475

Review 9.  Posterior fossa syndrome-a narrative review.

Authors:  Salima S Wahab; Samantha Hettige; Kshtij Mankad; Kristian Aquilina
Journal:  Quant Imaging Med Surg       Date:  2016-10

Review 10.  Medulloblastoma.

Authors:  Nathan E Millard; Kevin C De Braganca
Journal:  J Child Neurol       Date:  2015-09-02       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.